How Analysts Feel About G1 Therapeutics, Inc. (GTHX) After Today’s Huge Increase?

April 17, 2018 - By Vivian Park

The stock of G1 Therapeutics, Inc. (NASDAQ:GTHX) is a huge mover today! The stock increased 13.25% or $4.81 during the last trading session, reaching $41.1. About 125,604 shares traded. G1 Therapeutics, Inc. (NASDAQ:GTHX) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.
The move comes after 5 months positive chart setup for the $1.33 billion company. It was reported on Apr, 17 by We have $43.16 PT which if reached, will make NASDAQ:GTHX worth $66.50 million more.

Analysts await G1 Therapeutics, Inc. (NASDAQ:GTHX) to report earnings on May, 16. After $-0.60 actual EPS reported by G1 Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 6.67 % negative EPS growth.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. The company has market cap of $1.33 billion. It is developing trilaciclib, an intravenous cyclin-dependent kinases 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. It currently has negative earnings. The firm has a clinical trial collaboration agreement with AstraZeneca to evaluate AstraZeneca's epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Tagrisso (osimertinib) in combination with oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer; and a research partnership GeneCentric Therapeutics, Inc. to identify subtypes of lung cancer where the compound is likely to be efficacious.

G1 Therapeutics, Inc. (NASDAQ:GTHX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: